Low GSK-3β Immunoreactivity in Postmortem Frontal Cortex of Schizophrenic Patients

Abstract

These results are consistent with the notion that schizophrenia involves neurodevelopmental pathology. It remains to be investigated whether the active fraction of GSK-3beta, or its activity, is also low in frontal cortex of schizophrenic patients and if this is also reflected in other brain regions.